Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors

被引:60
作者
Sharma, Sanjai [1 ]
Lichtenstein, Alan [1 ]
机构
[1] Univ Calif Los Angeles, W Los Angeles & VA Med Ctr, Div Hematol Oncol, Los Angeles, CA 90073 USA
关键词
D O I
10.1182/blood-2007-11-124156
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The mechanism by which the glucocorticoid (GC) dexamethasone induces apoptosis in multiple myeloma (MM) cells is unknown, although previous work suggests that either transactivation through the glucocorticoid response element (GRE), transrepression of NF-kappa B, phosphorylation of RAFTK (Pyk2), or induction of Bim is important. We studied this question by ectopically expressing mutant glucocorticoid receptors (GRs) in the dexamethasone-resistant MM1 R cell line, which has lost its GR. Lentiviral-mediated reexpression of wild-type GR restored GRE transactivation, NF-KB transrepression, RAFTK phosphorylation, Bim induction, and dexamethasone-induced apoptosis. We then reexpressed 4 GR mutants, each possessing various molecular effects, into MM1 R cells. A perfect correlation was present between induction of GRE transactivation and induction of apoptosis. In contrast, NF-KB transrepression and RAFTK phosphorylation were not required for apoptosis. Although not required for dexamethasone-mediated apoptosis, NF-KB inhibition achieved by gene transfer suggested that NF-KB trans-repression could contribute to apoptosis in dexamethasone-treated cells. Dexamethasone treatment of MM1R cells expressing a mutant incapable of inducing apoptosis successfully resulted in RAFTK (Pyk2) phosphorylation and Bim induction indicating the latter GR-mediated events were not sufficient to induce apoptosis. MM1R cells expressing mutant GRs will be helpful in defining the molecular mechanisms of dexamethasone-induced apoptosis of myeloma cells.
引用
收藏
页码:1338 / 1345
页数:8
相关论文
共 31 条
[11]   Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells [J].
Chauhan, D ;
Kharbanda, S ;
Ogata, A ;
Urashima, M ;
Teoh, G ;
Robertson, M ;
Kufe, DW ;
Anderson, KC .
BLOOD, 1997, 89 (01) :227-234
[12]  
Chauhan D, 2000, J BIOL CHEM, V275, P27845
[13]  
DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107
[14]   TRANSCRIPTIONAL TRANSACTIVATION FUNCTIONS LOCALIZED TO THE GLUCOCORTICOID RECEPTOR-N TERMINUS ARE NECESSARY FOR STEROID INDUCTION OF LYMPHOCYTE APOPTOSIS [J].
DIEKEN, ES ;
MIESFELD, RL .
MOLECULAR AND CELLULAR BIOLOGY, 1992, 12 (02) :589-597
[15]   FUNCTIONAL DOMAINS OF THE HUMAN GLUCOCORTICOID RECEPTOR [J].
GIGUERE, V ;
HOLLENBERG, SM ;
ROSENFELD, MG ;
EVANS, RM .
CELL, 1986, 46 (05) :645-652
[16]   The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells [J].
Gomez-Bougie, P ;
Bataille, R ;
Amiot, M .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2004, 34 (11) :3156-3164
[17]   Characterization of the MM.1 human multiple myeloma (MM) cell lines: A model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells [J].
Greenstein, S ;
Krett, NL ;
Kurosawa, Y ;
Ma, CU ;
Chauhan, D ;
Hideshima, T ;
Anderson, KC ;
Rosen, ST .
EXPERIMENTAL HEMATOLOGY, 2003, 31 (04) :271-282
[18]   A DISTINCT MODULATING DOMAIN IN GLUCOCORTICOID RECEPTOR MONOMERS IN THE REPRESSION OF ACTIVITY OF THE TRANSCRIPTION FACTOR AP-1 [J].
HECK, S ;
KULLMANN, M ;
GAST, A ;
PONTA, H ;
RAHMSDORF, HJ ;
HERRLICH, P ;
CATO, ACB .
EMBO JOURNAL, 1994, 13 (17) :4087-4095
[19]  
HEIMBERG A, 1995, EMBO J, V14, P452
[20]   NF-κB as a therapeutic target in multiple myeloma [J].
Hideshima, T ;
Chauhan, D ;
Richardson, P ;
Mitsiades, C ;
Mitsiades, N ;
Hayashi, T ;
Munshi, N ;
Dang, L ;
Castro, A ;
Palombella, V ;
Adams, J ;
Anderson, KC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (19) :16639-16647